z-logo
open-access-imgOpen Access
Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F
Author(s) -
Rolf Kuestner,
David W. Taft,
Aaron C. Haran,
Cameron S. Brandt,
Ty Brender,
Karen D. Lum,
Brandon Harder,
Shan Okada,
Craig Ostrander,
James L. Kreindler,
Shean Aujla,
Brian Reardon,
Margaret Moore,
Pamela Shea,
Randall Schreckhise,
Thomas R. Bukowski,
Scott Presnell,
Patricia Guerra-Lewis,
Julia Parrish-Novak,
Jeff L. Ellsworth,
Stephen R. Jaspers,
Katherine E. Lewis,
Mark W. Appleby,
Jay K. Kolls,
Mark W. Rixon,
James W. West,
Zeren Gao,
Steven D. Levin
Publication year - 2007
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.179.8.5462
Subject(s) - receptor , proinflammatory cytokine , interleukin 17 , receptor antagonist , interleukin 1 receptor antagonist , interleukin , microbiology and biotechnology , biology , antagonist , interleukin 1 receptor, type ii , immunology , cytokine , inflammation , biochemistry , interleukin 5
The proinflammatory cytokines IL-17A and IL-17F have a high degree of sequence similarity and share many biological properties. Both have been implicated as factors contributing to the progression of inflammatory and autoimmune diseases. Moreover, reagents that neutralize IL-17A significantly ameliorate disease severity in several mouse models of human disease. IL-17A mediates its effects through interaction with its cognate receptor, the IL-17 receptor (IL-17RA). We report here that the IL-17RA-related molecule, IL-17RC is the receptor for IL-17F. Notably, both IL-17A and IL-17F bind to IL-17RC with high affinity, leading us to suggest that a soluble form of this molecule may serve as an effective therapeutic antagonist of IL-17A and IL-17F. We generated a soluble form of IL-17RC and demonstrate that it effectively blocks binding of both IL-17A and IL-17F, and that it inhibits signaling in response to these cytokines. Collectively, our work indicates that IL-17RC functions as a receptor for both IL-17A and IL-17F and that a soluble version of this protein should be an effective antagonist of IL-17A and IL-17F mediated inflammatory diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom